Codagenix Expands Senior Management Team With Three New Appointments
New Hires Bolster Codagenix s Operations, Regulatory Affairs and Clinical Trial Management
News provided by
Share this article
Share this article
NEW YORK, March 17, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been named Director of Operations. Additionally, Sally Yang, M.S., R.A.C. has been appointed Associate Director of Regulatory Affairs, and Lasmy Tea, M.S., M.P.H., has been named Associate Director of Clinical Project Management.
Share this article
Share this article
MONMOUTH JUNCTION, N.J., Jan. 21, 2021 /PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of David D. Cox, Ph.D., M.B.A., as Vice President – Global Regulatory Affairs.
Dr. Cox was most recently Vice President of Regulatory Affairs for tissue and regenerative technologies at Integra LifeSciences Corporation. He was responsible for successful regulatory approvals of new products and product extensions for the $480 million orthopedics and tissue technologies division. Dr. Cox led efforts to develop U.S. FDA Premarket Approvals (PMA), 510(k)s, and Investigational New Drugs (IND), as well as international registrations under the European Union (E.U.) Medical Device Directive (MDD) and the new Medical Device Re